Cytokinetics (CYTK)
NASDAQ: CYTK
· Real-Time Price · USD
56.97
0.65 (1.15%)
At close: Oct 03, 2025, 3:59 PM
56.01
-1.69%
After-hours: Oct 03, 2025, 05:03 PM EDT
1.15% (1D)
| Bid | 41.43 |
| Market Cap | 6.82B |
| Revenue (ttm) | 85.74M |
| Net Income (ttm) | -606.31M |
| EPS (ttm) | -5.2 |
| PE Ratio (ttm) | -10.96 |
| Forward PE | -9.88 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 72.84 |
| Volume | 2,441,028 |
| Avg. Volume (20D) | 2,325,536.9 |
| Open | 56.74 |
| Previous Close | 56.32 |
| Day's Range | 56.26 - 58.78 |
| 52-Week Range | 29.31 - 59.39 |
| Beta | 0.68 |
| Ex-Dividend Date | n/a |
About CYTK
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CYTK
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CYTK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsCytokinetics is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 days ago
+6.92%
Cytokinetics shares are trading higher. HC Wainwri...
Unlock content with
Pro Subscription
2 weeks ago
+0.65%
CYTK stock has given up its prior loss. Cytokinetics shares were trading lower after the company announced a $550 million private offering of convertible notes.
2 weeks ago · businesswire.com
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law FirmLOS ANGELES--(BUSINESS WIRE)---- $CYTK--CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm.
